NVDA
NVIDIA Corporation
NVDA has the edge over PATH overall, supported by stronger valuation and stronger modeled upside.
PATH
UiPath Inc.
PATH's outlook is improving, though it still trails on the overall score.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
PATH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
PATH's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over PATH in the historical PE scenario, which offers more potential upside but is not a forecast.
PATH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $13.10 | — |
| Cheap | 20x | $13.08 | -0.2% |
| Current | 20x | $13.10 | — |
| Fair | 23x | $15.26 | +16% |
| Expensive | 403x | $270 | +1960% |
Historical ranges are pointers, not guarantees.
PATH's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
PATH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
PATH has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA's earnings per share have climbed steadily: $7.91 over the past year, up 125% from the year before, and higher year over year for 13 quarters in a row.
PATH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.88 | +31% |
| Q3 2026 | $0.67 | +2133% |
| Q2 2026 | $0.60 | +$0.72 |
| Q1 2026 | $0.52 | +$0.65 |
| Q4 2025 | $0.42 | +$0.57 |
| Q3 2025 | $0.03 | +$0.22 |
| Q2 2025 | -$0.12 | +$0.03 |
| Q1 2025 | -$0.13 | +$0.03 |
| Q4 2024 | -$0.15 | +$0.13 |
PATH's earnings per share have climbed steadily: $0.67 over the past year, more than ten times what it earned the year before, and higher year over year for 18 quarters in a row.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over PATH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over PATH on profitability, with a higher operating margin.
PATH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $410.3M | +13% |
| Q2 2026 | $418.4M | +17% |
| Q1 2026 | $481.1M | +14% |
| Q4 2025 | $411.1M | +16% |
| Q3 2025 | $361.7M | +14% |
| Q2 2025 | $356.6M | +6.4% |
| Q1 2025 | $423.6M | +4.5% |
| Q4 2024 | $354.7M | +8.8% |
PATH's revenue has grown year over year every quarter since early 2021: $410M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +13 points |
| Q2 2026 | 6.7% | +11 points |
| Q1 2026 | 17% | +8.8 points |
| Q4 2025 | 3.2% | +15 points |
| Q3 2025 | -5.6% | +27 points |
| Q2 2025 | -4.6% | +10 points |
| Q1 2025 | 7.9% | +4.2 points |
| Q4 2024 | -12% | +4.9 points |
PATH's operating margin was 7.7% last quarter, up 13 points from the same quarter a year ago.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over PATH on cash flow, with more consistent year-over-year improvement.
PATH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $29.3M | -30% |
| Q2 2026 | $129.2M | +22% |
| Q1 2026 | $179.3M | +29% |
| Q4 2025 | $25.1M | +8.2% |
| Q3 2025 | $41.6M | -7.5% |
| Q2 2025 | $106.2M | +7.5% |
| Q1 2025 | $138.7M | -2.2% |
| Q4 2024 | $23.2M | -44% |
PATH generated $363M in free cash flow over the past year, up 17% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
PATH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -4.8M shares |
| 1 year | -3.7% | -19.9M shares |
| 3 years | -7.1% | -39.9M shares |
| 5 years | -0.7% | -3.5M shares |
| Available history | +6.3% | +30.9M shares |
PATH has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $24.8M |
| Q2 2026 | $243.8M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $101.6M |
| Q2 2025 | $227.5M |
| Q1 2025 | $9.3M |
| Q4 2024 | $162.7M |
PATH spent $269M buying back its own shares over the past year, down 46% from the year before.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
PATH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.4x | Net Cash |
| Q2 2026 | -5.2x | Net Cash |
| Q1 2026 | -11.8x | Net Cash |
| Q4 2025 | -29.4x | Net Cash |
PATH has the edge over NVDA on leverage, with a lower net debt burden relative to earnings.
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
PATH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 24.9 | Neutral |
PATH's weekly RSI is 50 (neutral) and its Stochastic is 25 (neutral).
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
PATH PE vs Technology Sector
| Metric | PATH | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 30% below |
| PE % | 20 | 42 | 22 pts below |
PATH has the edge over NVDA on valuation relative to its sector.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
PATH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.2 | 1% below |
| 20 week MA | $13.7 | 4% below |
| 50 week MA | $12.9 | 1.4% above |
| 100 week MA | $12.8 | 2.3% above |
| 200 week MA | $14.8 | 12% below |
PATH has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over PATH on returns for 2026, with the stronger performance.
PATH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $74.8 | $44.4 | -41% |
| 2022 | $44.4 | $12.1 | -73% |
| 2023 | $12.1 | $24.8 | +105% |
| 2024 | $24.8 | $12.9 | -48% |
| 2025 | $12.9 | $16.8 | +31% |
| 2026 YTD | $16.8 | $13.1 | -22% |
PATH's yearly returns have swung widely, from +105% in 2023 to −73% in 2022. It's down 22% so far in 2026.